<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (<z:chebi fb="113" ids="28364">EPA</z:chebi>) has <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> activity at early stages of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, relevant to chemoprevention of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the hypothesis that <z:chebi fb="113" ids="28364">EPA</z:chebi> also has anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> activity at later stages of colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, relevant to treatment of metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, via modulation of E-type PG synthesis </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL APPROACH: A BALB/c mouse model, in which intrasplenic injection of syngeneic MC-26 mouse <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells leads to development of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, was used </plain></SENT>
<SENT sid="3" pm="."><plain>Dietary <z:chebi fb="113" ids="28364">EPA</z:chebi> was administered in the free fatty acid (FFA) form for 2 weeks before and after ultrasound-guided intrasplenic injection of 1 × 10(6) MC-26 cells (n= 16 each group) </plain></SENT>
<SENT sid="4" pm="."><plain>KEY RESULTS: Treatment with 5% (w w(-1)) <z:chebi fb="113" ids="28364">EPA</z:chebi>-FFA was associated with a reduced MC-26 mouse <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell <z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">liver tumour</z:e> burden compared with control animals (median liver weight 1.03 g vs. 1.62 g; P &lt; 0.034) </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of 5% <z:chebi fb="113" ids="28364">EPA</z:chebi>-FFA was also linked to a significant increase in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:chebi fb="113" ids="28364">EPA</z:chebi> incorporation and lower intratumoural <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) levels (with concomitant increased production of <z:chebi fb="0" ids="26338">PGE</z:chebi>(3)) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">Liver tumours</z:e> from 5% <z:chebi fb="113" ids="28364">EPA</z:chebi>-FFA- treated mice demonstrated decreased 5-<z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-2-deoxyuridine-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell proliferation and reduced phosphorylated ERK 1/2 expression at the invasive edge of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>A concentration-dependent reduction in MC-26 CRC cell Transwell® migration following <z:chebi fb="113" ids="28364">EPA</z:chebi>-FFA treatment (50-200 µM) in vitro was rescued by exogenous <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) (10 µM) and <z:chebi fb="0" ids="26338">PGE</z:chebi>(1)-alcohol (1 µM) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS AND IMPLICATIONS: <z:chebi fb="113" ids="28364">EPA</z:chebi>-FFA inhibits MC-26 CRC cell <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="113" ids="28364">EPA</z:chebi> incorporation is associated with a '<z:chebi fb="0" ids="26338">PGE</z:chebi>(2) to <z:chebi fb="0" ids="26338">PGE</z:chebi>(3) switch' in <z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">liver tumours</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Inhibition of <z:chebi fb="0" ids="26338">PGE</z:chebi>(2)-EP(4) receptor-dependent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell motility probably contributes to the <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> activity of <z:chebi fb="113" ids="28364">EPA</z:chebi> </plain></SENT>
</text></document>